Impact of


Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
12 2020
Historique:
received: 13 01 2020
accepted: 07 04 2020
pubmed: 3 5 2020
medline: 6 3 2021
entrez: 3 5 2020
Statut: ppublish

Résumé

Prostate-specific membrane antigen (PSMA) ligand PET induces management changes in patients with prostate cancer. We aim to better characterize the impact of

Identifiants

pubmed: 32358094
pii: jnumed.120.242180
doi: 10.2967/jnumed.120.242180
pmc: PMC9364898
doi:

Substances chimiques

Gallium Isotopes 0
Gallium Radioisotopes 0
Oligopeptides 0
gallium 68 PSMA-11 0
Edetic Acid 9G34HU7RV0

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1793-1799

Subventions

Organisme : NCI NIH HHS
ID : R01 CA212148
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016042
Pays : United States

Informations de copyright

© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Références

BJU Int. 2018 Nov;122(5):783-793
pubmed: 29726071
Eur Urol. 2017 Apr;71(4):630-642
pubmed: 27591931
J Nucl Med. 2015 Aug;56(8):1185-90
pubmed: 26112024
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
Lancet Oncol. 2019 Sep;20(9):1286-1294
pubmed: 31375469
J Clin Oncol. 2008 May 1;26(13):2155-61
pubmed: 18362365
Eur J Nucl Med Mol Imaging. 2019 Apr;46(4):889-900
pubmed: 30488099
J Nucl Med. 2018 Mar;59(3):434-441
pubmed: 29242398
Eur Urol. 2020 Apr;77(4):403-417
pubmed: 30773328
J Nucl Med. 2017 Dec;58(12):1956-1961
pubmed: 28522741
J Nucl Med. 2008 Dec;49(12):1928-35
pubmed: 18997054
J Nucl Med. 2018 Mar;59(3):469-478
pubmed: 29123012
Eur J Nucl Med Mol Imaging. 2016 Nov;43(12):2114-2121
pubmed: 27290607
Eur Urol Focus. 2018 Sep;4(5):686-693
pubmed: 28753806
JAMA Oncol. 2019 Jun 01;5(6):856-863
pubmed: 30920593
J Nucl Med. 2018 Jan;59(1):82-88
pubmed: 28646014
BMC Cancer. 2019 Jan 7;19(1):18
pubmed: 30616601
Eur Urol. 2018 Aug;74(2):179-190
pubmed: 29678358
JAMA. 1999 May 5;281(17):1591-7
pubmed: 10235151
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1258-1268
pubmed: 28497198
J Natl Compr Canc Netw. 2019 May 1;17(5):479-505
pubmed: 31085757
J Nucl Med. 2015 May;56(5):668-74
pubmed: 25791990

Auteurs

Wolfgang P Fendler (WP)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany.

Justin Ferdinandus (J)

Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany.

Johannes Czernin (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Matthias Eiber (M)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Department of Nuclear Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

Robert R Flavell (RR)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

Spencer C Behr (SC)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

I-Wei K Wu (IK)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

Courtney Lawhn-Heath (C)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

Miguel H Pampaloni (MH)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

Robert E Reiter (RE)

Department of Urology, UCLA Medical Center, UCLA, Los Angeles, California.

Matthew B Rettig (MB)

Department of Urology, UCLA Medical Center, UCLA, Los Angeles, California.
Division of Hematology/Oncology, Department of Medicine, UCLA, and Division of Hematology/Oncology, Department of Medicine, VA Greater Los Angeles, Los Angeles, California; and.

Jeannine Gartmann (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Vishnu Murthy (V)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.

Roger Slavik (R)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Peter R Carroll (PR)

Department of Urology, University of California, San Francisco, San Francisco, California.

Ken Herrmann (K)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.
Department of Nuclear Medicine, University of Duisburg-Essen and German Cancer Consortium (DKTK), University Hospital Essen, Germany.

Jeremie Calais (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, California.

Thomas A Hope (TA)

Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California thomas.hope@ucsf.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH